BioSpace News Archive

The menace of drugs has been dogging our society for decades on end now.

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to margetuximab, an investigational, Fc-engineered monoclonal antibody targeting HER2 for the treatment of gastric and gastroesophageal junction c

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it has dosed the first healthy volunteer in a Phase 1 study with ARCT-810, the Company’s messenger RNA (mRNA)-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to five new employees.

Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it is relocating its corporate offices and CLIA-certified, CAP-accredited high complexity laboratory to a new location i

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that, at the annual general and special meeting (the “ Meeting ”) of shareholders of the Company (“ Shareholders ”) that was held yesterday, all five nominees for the board of directors of the Company were elected, the voting results of which are as follows: Director Votes

he company intends to focus on the business development of its 27Health Inc. subsidiary. 27Health Inc. is dedicated to financing and marketing innovative, healthcare related products that are and will benefit from the permanent changes caused by the COVID-19 pandemic.

- CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate - CEPI and CSL will share costs associated with the clinical development and manufacture of the vaccine candidate - A vaccine is anticipated to be available in 2021 if clinical trials are successful

Three immunology projects will explore the creation of cancer-targeted T-cells within the thymus, and the impact of gut microbiota in patients with multiple myeloma and other cancers including those receiving stem cell transplantation [05-June-2020] HACKENSACK, N.J. and NEW YORK , June 5, 2020 /PRNewswire/ -- As part of the Memorial Sloan Kettering – Hackensack Meri

Published In Vivo Study Concludes Hemovent’s MOBYBOX™ ECLS Device Provides “Excellent (Long-Term) Safety and Physiologic Efficacy”